Free Trial

Denali Therapeutics (DNLI) Financials

Denali Therapeutics logo
$14.88 +0.28 (+1.91%)
Closing price 04/23/2025 03:58 PM Eastern
Extended Trading
$14.69 -0.19 (-1.26%)
As of 04/23/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Denali Therapeutics

Annual Income Statements for Denali Therapeutics

This table shows Denali Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-87 -88 -37 -197 71 -293 -330 -138 -421
Consolidated Net Income / (Loss)
-87 -88 -36 -198 71 -291 -326 -145 -423
Net Income / (Loss) Continuing Operations
-87 -88 -36 -198 71 -291 -326 -145 -423
Total Pre-Tax Income
-87 -88 -46 -213 63 -296 -326 -145 -423
Total Operating Income
-87 -90 -46 -213 63 -296 -341 -197 -487
Total Gross Profit
0.00 0.00 129 27 336 49 108 331 0.00
Total Revenue
0.00 0.00 129 27 336 49 108 331 0.00
Operating Revenue
0.00 0.00 129 27 336 49 108 331 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
87 90 176 240 273 344 449 527 487
Selling, General & Admin Expense
12 16 32 46 60 79 90 103 105
Research & Development Expense
76 74 143 193 213 265 359 424 396
Other Special Charges / (Income)
- - - - - - - 0.00 -15
Total Other Income / (Expense), net
0.00 1.96 0.00 0.00 0.00 0.00 15 52 65
Interest & Investment Income
- - - - - - 15 52 65
Income Tax Expense
- 0.00 0.00 -0.35 0.82 -0.58 0.02 0.03 0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
0.37 -0.01 0.28 -1.00 0.60 2.25 4.39 -7.53 -1.38
Basic Earnings per Share
($13.49) ($5.89) ($0.39) ($2.07) $0.65 ($2.39) ($2.60) ($1.06) ($2.57)
Weighted Average Basic Shares Outstanding
6.42M 14.96M 92.62M 95.61M 108.97M 121.52M 125.53M 137.37M 164.47M
Diluted Earnings per Share
($13.49) ($5.89) ($0.39) ($2.07) $0.63 ($2.39) ($2.60) ($1.06) ($2.57)
Weighted Average Diluted Shares Outstanding
6.42M 14.96M 92.62M 95.61M 112.70M 121.52M 125.53M 137.37M 164.47M
Weighted Average Basic & Diluted Shares Outstanding
6.42M 14.96M 92.62M 95.61M 108.97M 122.83M 136.68M 139.16M 145.22M

Quarterly Income Statements for Denali Therapeutics

This table shows Denali Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-103 -94 -105 184 -99 -118 -104 -100 -99 -118
Consolidated Net Income / (Loss)
-103 -99 -110 183 -99 -119 -102 -99 -107 -115
Net Income / (Loss) Continuing Operations
-103 -99 -110 183 -99 -119 -102 -99 -107 -115
Total Pre-Tax Income
-103 -95 -110 183 -99 -119 -102 -99 -107 -115
Total Operating Income
-107 -105 -121 170 -114 -133 -118 -117 -123 -130
Total Operating Expenses
111 116 156 124 115 133 118 117 123 130
Selling, General & Admin Expense
23 24 27 26 25 25 25 25 25 30
Research & Development Expense
88 92 129 98 90 108 107 91 98 100
Total Other Income / (Expense), net
4.19 11 11 13 14 13 16 18 16 15
Interest & Investment Income
- - 11 13 14 13 16 18 16 15
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
-0.42 -4.97 -4.37 -1.08 -0.79 -1.29 1.94 1.36 -8.19 3.51
Basic Earnings per Share
($0.84) ($0.75) ($0.80) $1.34 ($0.72) ($0.88) ($0.68) ($0.59) ($0.63) ($0.67)
Weighted Average Basic Shares Outstanding
123.47M 125.53M 136.52M 137.05M 137.64M 137.37M 149.40M 168.83M 169.46M 164.47M
Diluted Earnings per Share
($0.84) ($0.75) ($0.80) $1.30 ($0.72) ($0.84) ($0.68) ($0.59) ($0.63) ($0.67)
Weighted Average Diluted Shares Outstanding
123.47M 125.53M 136.52M 140.93M 137.64M 137.37M 149.40M 168.83M 169.46M 164.47M
Weighted Average Basic & Diluted Shares Outstanding
135.81M 136.68M 136.89M 137.42M 138.20M 139.16M 142.61M 143.17M 143.92M 145.22M

Annual Cash Flow Statements for Denali Therapeutics

This table details how cash moves in and out of Denali Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
9.56 179 -140 2.33 428 -214 -75 -91 48
Net Cash From Operating Activities
-72 -77 50 -152 416 -211 -245 -358 -348
Net Cash From Continuing Operating Activities
-72 -77 50 -152 416 -211 -245 -358 -348
Net Income / (Loss) Continuing Operations
-87 -88 -36 -198 71 -291 -326 -145 -423
Consolidated Net Income / (Loss)
-87 -88 -36 -198 71 -291 -326 -145 -423
Depreciation Expense
1.47 3.08 7.42 7.99 8.53 8.59 10 17 7.80
Amortization Expense
0.30 0.75 -2.71 -5.02 0.06 8.75 0.00 -44 1.20
Non-Cash Adjustments To Reconcile Net Income
8.23 4.41 19 40 48 82 64 104 49
Changes in Operating Assets and Liabilities, net
4.74 3.31 63 2.92 288 -20 7.28 -290 17
Net Cash From Investing Activities
-219 -41 -287 148 -623 -22 -141 249 -89
Net Cash From Continuing Investing Activities
-219 -41 -287 148 -623 -22 -141 249 -89
Purchase of Property, Plant & Equipment
-6.13 -2.88 -3.39 -18 -3.10 -8.50 -18 -13 -16
Purchase of Investments
-227 -180 -558 -370 -1,285 -1,423 -1,115 -1,814 -1,230
Sale and/or Maturity of Investments
14 141 274 535 665 1,410 991 2,076 1,157
Net Cash From Financing Activities
300 296 97 6.19 635 19 311 18 484
Net Cash From Continuing Financing Activities
300 296 97 6.19 635 19 311 18 484
Issuance of Common Equity
0.00 266 94 0.00 614 19 311 18 517
Other Financing Activities, net
0.11 0.73 4.00 6.19 21 - 0.00 0.00 -32
Cash Interest Paid
- - - - - - 0.00 0.00 0.30
Cash Income Taxes Paid
- - - - 0.00 0.21 0.05 0.00 0.00

Quarterly Cash Flow Statements for Denali Therapeutics

This table details how cash moves in and out of Denali Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-36 99 -150 64 16 -21 -67 14 16 84
Net Cash From Operating Activities
-57 -73 -59 -113 -87 -99 -114 -91 -59 -84
Net Cash From Continuing Operating Activities
-57 -73 -59 -113 -87 -99 -114 -91 -59 -84
Net Income / (Loss) Continuing Operations
-103 -99 -110 183 -99 -119 -102 -99 -107 -115
Consolidated Net Income / (Loss)
-103 -99 -110 183 -99 -119 -102 -99 -107 -115
Depreciation Expense
2.14 4.09 10 2.29 2.22 2.18 2.16 1.94 1.84 1.85
Amortization Expense
-0.69 -1.43 -7.85 -12 19 -44 -11 -10 21 0.77
Non-Cash Adjustments To Reconcile Net Income
24 -8.61 27 26 -5.21 57 12 24 -5.14 18
Changes in Operating Assets and Liabilities, net
21 32 22 -313 -4.41 5.85 -16 -8.16 30 11
Net Cash From Investing Activities
15 -128 -93 168 101 73 -453 99 94 172
Net Cash From Continuing Investing Activities
15 -128 -93 168 101 73 -453 99 94 172
Purchase of Property, Plant & Equipment
-6.05 -4.85 -2.79 -5.85 -2.07 -2.24 -2.15 -4.79 -3.88 -5.09
Purchase of Investments
-123 -487 -524 -378 -498 -414 -834 -122 -100 -174
Sale and/or Maturity of Investments
144 364 434 552 601 489 383 225 198 351
Net Cash From Financing Activities
5.15 300 1.60 9.02 2.49 4.71 500 6.76 -19 -4.17
Net Cash From Continuing Financing Activities
5.15 300 1.60 9.02 2.49 4.71 500 6.76 -19 -4.17
Issuance of Common Equity
5.15 300 1.60 9.02 2.49 4.71 500 6.76 5.46 4.16
Other Financing Activities, net
- - - - - - - - - -8.32
Cash Interest Paid
- - - - - - - - - 0.18

Annual Balance Sheets for Denali Therapeutics

This table presents Denali Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
487 662 553 1,604 1,404 1,460 1,154 1,374
Total Current Assets
410 481 430 1,496 897 1,372 1,064 864
Cash & Equivalents
218 77 79 507 293 218 127 175
Short-Term Investments
188 387 336 963 572 1,118 907 657
Prepaid Expenses
3.38 17 15 20 31 36 30 32
Plant, Property, & Equipment, net
15 25 47 41 39 44 46 55
Total Noncurrent Assets
62 156 76 68 468 44 44 455
Long-Term Investments
61 148 40 33 425 - 0.00 359
Noncurrent Note & Lease Receivables
- - - - - - 0.00 48
Other Noncurrent Operating Assets
1.44 8.11 37 35 43 44 44 48
Total Liabilities & Shareholders' Equity
487 662 553 1,604 1,404 1,460 1,154 1,374
Total Liabilities
21 115 158 454 442 418 123 144
Total Current Liabilities
14 33 45 72 378 364 78 102
Accounts Payable
2.72 1.89 2.59 1.07 4.78 2.79 9.48 11
Accrued Expenses
5.36 - - - - 67 68 91
Total Noncurrent Liabilities
6.76 82 113 382 64 54 45 42
Other Noncurrent Operating Liabilities
0.47 58 113 382 64 53 45 42
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
466 547 395 1,151 962 1,042 1,031 1,230
Total Preferred & Common Equity
466 547 395 1,151 962 1,042 1,031 1,230
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
466 547 395 1,151 962 1,042 1,031 1,230
Common Stock
658 775 820 1,505 1,610 2,020 2,147 2,767
Retained Earnings
-192 -228 -426 -354 -645 -971 -1,116 -1,539
Accumulated Other Comprehensive Income / (Loss)
-0.37 -0.65 0.35 -0.25 -2.50 -6.89 0.64 2.02

Quarterly Balance Sheets for Denali Therapeutics

This table presents Denali Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,228 1,409 1,306 1,237 1,581 1,503 1,454
Total Current Assets
1,139 1,325 1,224 1,143 974 928 869
Cash & Equivalents
119 68 132 148 61 75 91
Short-Term Investments
987 1,220 1,059 961 876 821 746
Prepaid Expenses
32 37 33 34 37 32 32
Plant, Property, & Equipment, net
42 42 40 48 47 48 51
Total Noncurrent Assets
47 42 42 46 561 526 534
Long-Term Investments
0.00 - - 7.91 491 451 445
Noncurrent Note & Lease Receivables
- - - - - - 39
Other Noncurrent Operating Assets
47 42 42 38 70 75 50
Total Liabilities & Shareholders' Equity
1,228 1,409 1,306 1,237 1,581 1,503 1,454
Total Liabilities
416 443 119 118 126 116 136
Total Current Liabilities
361 391 69 71 83 75 87
Accounts Payable
8.98 11 15 12 12 14 9.59
Accrued Expenses
41 77 36 36 43 33 38
Current Deferred Revenue
- - - - 13 10 16
Current Employee Benefit Liabilities
13 7.37 10 16 8.05 9.56 15
Other Current Liabilities
298 296 7.62 7.01 7.51 7.77 8.04
Total Noncurrent Liabilities
56 52 50 47 43 41 48
Other Noncurrent Operating Liabilities
56 52 50 47 43 41 48
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
811 967 1,187 1,118 1,455 1,387 1,318
Total Preferred & Common Equity
811 967 1,187 1,118 1,455 1,387 1,318
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
811 967 1,187 1,118 1,455 1,387 1,318
Common Stock
1,695 2,050 2,086 2,116 2,675 2,707 2,737
Retained Earnings
-872 -1,081 -897 -997 -1,218 -1,317 -1,424
Accumulated Other Comprehensive Income / (Loss)
-12 -2.52 -1.44 -0.65 -1.30 -2.66 5.53

Annual Metrics and Ratios for Denali Therapeutics

This table displays calculated financial ratios and metrics derived from Denali Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% -79.35% 1,158.19% -85.50% 122.90% 204.74% -100.00%
EBITDA Growth
0.00% 1.53% 50.61% -404.57% 133.92% -490.46% -18.66% 32.22% -113.62%
EBIT Growth
0.00% -0.86% 47.42% -359.73% 129.42% -571.56% -15.21% 42.27% -147.76%
NOPAT Growth
0.00% -3.10% 48.56% -359.73% 141.48% -434.48% -15.21% 42.27% -147.76%
Net Income Growth
0.00% -1.77% 58.90% -445.29% 136.00% -508.49% -12.19% 55.45% -191.12%
EPS Growth
0.00% 56.34% 93.38% -430.77% 130.43% -479.37% -8.79% 59.23% -142.45%
Operating Cash Flow Growth
0.00% -6.57% 165.40% -402.45% 374.55% -150.80% -15.77% -46.29% 2.88%
Free Cash Flow Firm Growth
0.00% 0.00% 151.18% -586.58% 329.17% -165.17% -18.66% -56.57% 10.57%
Invested Capital Growth
0.00% 0.00% -5,436.69% 7.62% -483.02% 6.62% 10.59% 98.79% 1,167.75%
Revenue Q/Q Growth
0.00% 0.00% 3,607.23% -81.94% 1,327.36% -86.21% -2.02% -3.02% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 70.41% -172.08% 130.64% -770.66% -10.02% -45.50% 8.97%
EBIT Q/Q Growth
0.00% 0.00% 67.94% -164.16% 126.23% -1,262.18% -9.03% -16.07% 0.56%
NOPAT Q/Q Growth
0.00% 0.00% 67.94% -84.91% 136.98% -913.52% -9.03% -16.07% 0.56%
Net Income Q/Q Growth
0.00% 0.00% 84.02% -922.06% 131.23% -1,082.85% -7.74% -16.71% 1.10%
EPS Q/Q Growth
0.00% 0.00% -18.18% -213.64% 128.38% -568.63% -5.26% -9.28% 6.20%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 181.62% -1,310.27% 386.20% -157.44% -3.02% -7.83% 4.12%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -114.39% 365.49% -184.42% -1.08% -3.22% -1.14%
Invested Capital Q/Q Growth
0.00% 0.00% -16.77% 6.76% -255.45% 5.14% 0.33% -404.02% 4.13%
Profitability Metrics
- - - - - - - - -
Gross Margin
0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin
0.00% 0.00% -32.26% -787.96% 21.24% -572.14% -304.58% -67.75% 0.00%
Operating Margin
0.00% 0.00% -35.90% -799.10% 18.69% -607.78% -314.16% -59.51% 0.00%
EBIT Margin
0.00% 0.00% -35.90% -799.10% 18.69% -607.78% -314.16% -59.51% 0.00%
Profit (Net Income) Margin
0.00% 0.00% -28.06% -740.74% 21.19% -597.15% -300.56% -43.94% 0.00%
Tax Burden Percent
99.11% 100.00% 78.15% 92.70% 113.42% 98.25% 100.01% 100.02% 100.02%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 95.66% 73.82% 86.74%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 1.31% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -18.93% -7.16% -41.97% 9.21% -27.51% -32.52% -14.01% -37.40%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,007.57%
Operating Return on Assets (OROA)
0.00% 0.00% -8.07% -35.09% 5.81% -19.66% -23.79% -15.05% 0.00%
Return on Assets (ROA)
0.00% 0.00% -6.31% -32.52% 6.59% -19.32% -22.76% -11.11% 0.00%
Return on Common Equity (ROCE)
0.00% -18.93% -7.16% -41.97% 9.21% -27.51% -32.52% -14.01% -37.40%
Return on Equity Simple (ROE_SIMPLE)
0.00% -18.93% -6.63% -50.04% 6.18% -30.20% -31.27% -14.09% -34.38%
Net Operating Profit after Tax (NOPAT)
-61 -63 -32 -149 62 -207 -239 -138 -341
NOPAT Margin
0.00% 0.00% -25.13% -559.37% 18.44% -425.44% -219.91% -41.66% 0.00%
Net Nonoperating Expense Percent (NNEP)
0.00% -10.74% -0.70% -9.07% 0.94% -5.98% -6.66% -0.64% -7.33%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - -22.88% -13.36% -27.74%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 25.05% 174.23% 17.97% 162.47% 83.42% 31.27% 0.00%
R&D to Revenue
0.00% 0.00% 110.86% 724.87% 63.34% 545.31% 330.74% 128.24% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 135.90% 899.10% 81.32% 707.78% 414.16% 159.51% 0.00%
Earnings before Interest and Taxes (EBIT)
-87 -88 -46 -213 63 -296 -341 -197 -487
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-86 -84 -42 -210 71 -278 -330 -224 -478
Valuation Ratios
- - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 3.59 4.24 8.73 5.66 3.62 2.88 2.39
Price to Tangible Book Value (P/TBV)
0.00 0.00 3.59 4.24 8.73 5.66 3.62 2.88 2.39
Price to Revenue (P/Rev)
0.00 0.00 15.19 62.71 29.92 111.93 34.82 8.97 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 142.39 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.70% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 45.85
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 10.45 45.64 25.45 85.41 22.50 5.84 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 119.80 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 136.20 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 138.01 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 26.93 0.00 20.53 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 42.59 0.00 24.17 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -1.00 -1.07 -1.13 -1.27 -1.32 -1.31 -1.14 -0.98
Leverage Ratio
0.00 1.04 1.13 1.29 1.40 1.42 1.43 1.26 1.12
Compound Leverage Factor
0.00 1.04 1.13 1.29 1.40 1.42 1.37 0.93 0.97
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 10.52 4.87 14.38 6.54 4.63 13.87 10.11
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - -
Current Ratio
0.00 28.92 14.67 9.48 20.86 2.37 3.77 13.65 8.46
Quick Ratio
0.00 28.68 14.16 9.16 20.58 2.29 3.67 13.27 8.14
Cash Flow Metrics
- - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -62 32 -154 353 -230 -273 -428 -383
Operating Cash Flow to CapEx
-1,172.29% -2,665.57% 1,477.04% -845.90% 13,445.95% -2,486.93% -1,372.26% -2,766.76% -2,185.11%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - -
Asset Turnover
0.00 0.00 0.22 0.04 0.31 0.03 0.08 0.25 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 14.10 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 6.44 0.74 7.67 1.22 2.62 7.37 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 25.88 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 25.88 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - -
Invested Capital
0.00 -1.18 -65 -60 -352 -329 -294 -3.56 38
Invested Capital Turnover
0.00 0.00 -3.88 -0.42 -1.63 -0.14 -0.35 -2.22 0.00
Increase / (Decrease) in Invested Capital
0.00 -1.18 -64 4.98 -292 23 35 290 42
Enterprise Value (EV)
0.00 0.00 1,350 1,218 8,542 4,156 2,441 1,931 1,741
Market Capitalization
0.00 0.00 1,962 1,673 10,044 5,447 3,777 2,966 2,933
Book Value per Share
$0.00 $31.13 $5.76 $4.11 $9.59 $7.88 $7.68 $7.46 $8.54
Tangible Book Value per Share
$0.00 $31.13 $5.76 $4.11 $9.59 $7.88 $7.68 $7.46 $8.54
Total Capital
0.00 466 547 395 1,151 962 1,042 1,031 1,230
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -467 -612 -455 -1,502 -1,291 -1,336 -1,035 -1,192
Capital Expenditures (CapEx)
6.13 2.88 3.39 18 3.10 8.50 18 13 16
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -11 -16 -31 -46 -346 -328 -48 -70
Debt-free Net Working Capital (DFNWC)
0.00 395 448 385 1,424 519 1,008 986 762
Net Working Capital (NWC)
0.00 395 448 385 1,424 519 1,008 986 762
Net Nonoperating Expense (NNE)
25 25 3.78 48 -9.24 84 87 7.53 82
Net Nonoperating Obligations (NNO)
0.00 -467 -612 -455 -1,502 -1,291 -1,336 -1,035 -1,192
Total Depreciation and Amortization (D&A)
1.77 3.84 4.71 2.97 8.59 17 10 -27 8.99
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% -12.58% -114.96% -13.63% -711.90% -302.24% -14.63% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 346.90% 1,441.96% 424.23% 1,066.54% 929.72% 298.35% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 346.90% 1,441.96% 424.23% 1,066.54% 929.72% 298.35% 0.00%
Earnings Adjustments
- - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($0.39) ($2.07) $0.65 ($2.39) ($2.60) ($1.06) ($2.57)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 95.29M 105.42M 108.97M 121.52M 125.53M 137.37M 164.47M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.39) ($2.07) $0.63 ($2.39) ($2.60) ($1.06) ($2.57)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 95.29M 105.42M 108.97M 121.52M 125.53M 137.37M 164.47M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($0.39) ($2.07) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 92.62M 95.61M 108.97M 122.83M 136.68M 139.16M 145.22M
Normalized Net Operating Profit after Tax (NOPAT)
-61 -63 -32 -149 62 -207 -239 -138 -351
Normalized NOPAT Margin
0.00% 0.00% -25.13% -559.37% 18.44% -425.44% -219.91% -41.66% 0.00%
Pre Tax Income Margin
0.00% 0.00% -35.90% -799.10% 18.69% -607.78% -300.54% -43.93% 0.00%
Debt Service Ratios
- - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -3.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Denali Therapeutics

This table displays calculated financial ratios and metrics derived from Denali Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-32.66% -17.83% -16.61% 460.45% -64.40% 0.00% -100.00% -100.00% -100.00% 0.00%
EBITDA Growth
-26.13% -41.45% -88.91% 373.96% 9.48% -69.79% -6.28% -177.35% -8.84% 27.03%
EBIT Growth
-20.69% -36.60% -81.68% 377.59% -10.16% -25.85% 2.57% -168.39% -8.25% 2.06%
NOPAT Growth
-25.58% -36.60% -81.68% 496.55% -5.87% -25.85% 2.57% -147.87% -8.25% 2.06%
Net Income Growth
-22.12% -31.11% -68.32% 411.91% 3.82% -21.07% 7.27% -154.00% -7.89% 3.95%
EPS Growth
-21.74% -20.97% -50.94% 370.83% 14.29% -12.00% 15.00% -145.38% 12.50% 20.24%
Operating Cash Flow Growth
-37.68% -10.95% 18.45% -163.81% -53.14% -35.77% -93.22% 19.39% 32.31% 15.15%
Free Cash Flow Firm Growth
-167.67% -40.42% 49.03% -11.25% -196.06% -252.95% -720.00% -21.19% 67.64% 65.43%
Invested Capital Growth
14.90% 10.59% -11.00% 98.51% 100.40% 98.79% 108.67% 1,061.39% 3,017.35% 1,167.75%
Revenue Q/Q Growth
-93.22% 188.93% 241.74% 736.98% -99.57% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-73.05% -0.82% -13.71% 235.92% -157.18% -89.11% 11.62% 1.08% 19.54% -26.79%
EBIT Q/Q Growth
-68.20% -1.98% -14.69% 241.11% -166.75% -16.50% 11.21% 0.95% -5.66% -5.41%
NOPAT Q/Q Growth
-75.01% 1.99% -14.69% 301.59% -146.72% -16.50% 11.21% 0.95% -5.66% -5.41%
Net Income Q/Q Growth
-75.70% 4.47% -11.25% 267.04% -154.18% -20.25% 14.79% 2.73% -8.25% -7.05%
EPS Q/Q Growth
-75.00% 10.71% -6.67% 262.50% -155.38% -16.67% 19.05% 13.24% -6.78% -6.35%
Operating Cash Flow Q/Q Growth
-32.98% -27.38% 19.08% -92.46% 22.80% -12.93% -15.17% 19.71% 35.17% -41.56%
Free Cash Flow Firm Q/Q Growth
-35.97% 14.46% 51.45% -97.00% -261.85% -1.98% -12.79% 70.88% 3.38% -8.96%
Invested Capital Q/Q Growth
-5.86% 0.33% -9.52% 98.71% 128.11% -404.02% 883.89% 43.50% -8.85% 4.13%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-2,861.65% -998.57% -337.56% 54.82% -7,276.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-3,020.12% -1,024.45% -343.80% 57.96% -8,981.45% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-2,902.47% -1,024.45% -343.80% 57.96% -8,981.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-2,902.47% -959.62% -312.40% 62.35% -7,841.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 104.14% 100.00% 100.00% 100.00% 100.03% 100.00% 100.00% 100.00% 100.06%
Interest Burden Percent
100.00% 89.95% 90.87% 107.57% 87.31% 90.10% 86.48% 84.93% 87.02% 88.32%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-33.18% -32.52% -39.32% -12.40% -12.90% -14.01% -11.33% 0.00% -35.09% -37.40%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -35,431.77% 0.00% -1,739.95% -951.31% -2,010.20% -1,007.57%
Operating Return on Assets (OROA)
-239.98% -77.58% -25.55% 15.31% -2,484.20% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-239.98% -72.67% -23.22% 16.47% -2,168.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-33.18% -32.52% -39.32% -12.40% -12.90% -14.01% -11.33% 0.00% -35.09% -37.40%
Return on Equity Simple (ROE_SIMPLE)
-37.29% 0.00% -38.33% -10.82% -11.13% 0.00% -9.43% -30.26% -32.42% 0.00%
Net Operating Profit after Tax (NOPAT)
-75 -74 -85 170 -80 -93 -82 -82 -86 -91
NOPAT Margin
-2,114.08% -717.11% -240.66% 57.96% -6,287.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.28% -1.90% -2.02% 1.10% -1.77% -2.25% -1.43% -1.37% -1.75% -2.14%
Return On Investment Capital (ROIC_SIMPLE)
- -7.07% - - - -9.00% - - - -7.39%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
653.53% 228.69% 77.23% 8.88% 1,998.82% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
2,466.59% 895.76% 366.57% 33.16% 7,082.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
3,120.12% 1,124.45% 443.80% 42.04% 9,081.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-103 -105 -121 170 -114 -133 -118 -117 -123 -130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-102 -103 -119 161 -92 -174 -126 -125 -100 -127
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
4.67 3.62 3.26 3.40 2.54 2.88 1.95 2.39 3.16 2.39
Price to Tangible Book Value (P/TBV)
4.67 3.62 3.26 3.40 2.54 2.88 1.95 2.39 3.16 2.39
Price to Revenue (P/Rev)
34.20 34.82 31.04 11.77 8.32 8.97 9.60 2,613.56 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 1,468.25 0.00 50.50 49.09 79.19 45.85
Enterprise Value to Revenue (EV/Rev)
24.21 22.50 18.34 8.30 5.04 5.84 4.77 1,550.39 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.35 -1.31 -1.32 -1.14 -1.15 -1.14 -1.12 -0.99 -0.98 -0.98
Leverage Ratio
1.47 1.43 1.45 1.25 1.28 1.26 1.23 1.09 1.10 1.12
Compound Leverage Factor
1.47 1.29 1.32 1.35 1.12 1.14 1.07 0.93 0.96 0.99
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
5.03 5.16 3.78 21.18 14.24 14.05 13.08 16.40 17.46 10.97
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
3.16 3.77 3.39 17.65 16.06 13.65 11.79 12.46 9.98 8.46
Quick Ratio
3.07 3.67 3.29 17.17 15.58 13.27 11.34 12.02 9.61 8.14
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-127 -109 -53 -104 -376 -383 -432 -126 -122 -132
Operating Cash Flow to CapEx
-942.91% -1,498.52% -2,110.62% -1,934.51% -4,224.52% -4,414.18% -5,284.65% -1,905.98% -1,522.63% -1,644.05%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.08 0.08 0.07 0.26 0.28 0.25 0.20 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
2.71 2.62 2.54 8.74 7.59 7.37 6.64 0.03 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-295 -294 -322 -4.16 1.17 -3.56 28 40 36 38
Invested Capital Turnover
-0.35 -0.35 -0.33 -2.43 -2.32 -2.22 -2.01 0.07 0.00 0.00
Increase / (Decrease) in Invested Capital
52 35 -32 274 296 290 350 44 35 42
Enterprise Value (EV)
2,680 2,441 1,861 2,849 1,718 1,931 1,408 1,964 2,888 1,741
Market Capitalization
3,786 3,777 3,149 4,040 2,835 2,966 2,836 3,311 4,170 2,933
Book Value per Share
$6.58 $7.68 $7.07 $8.67 $8.14 $7.46 $9.74 $9.73 $9.21 $8.54
Tangible Book Value per Share
$6.58 $7.68 $7.07 $8.67 $8.14 $7.46 $9.74 $9.73 $9.21 $8.54
Total Capital
811 1,042 967 1,187 1,118 1,031 1,455 1,387 1,318 1,230
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-1,106 -1,336 -1,288 -1,191 -1,117 -1,035 -1,428 -1,347 -1,282 -1,192
Capital Expenditures (CapEx)
6.05 4.85 2.79 5.85 2.07 2.24 2.15 4.79 3.88 5.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-328 -328 -354 -36 -38 -48 -46 -42 -55 -70
Debt-free Net Working Capital (DFNWC)
778 1,008 934 1,155 1,072 986 891 854 782 762
Net Working Capital (NWC)
778 1,008 934 1,155 1,072 986 891 854 782 762
Net Nonoperating Expense (NNE)
28 25 25 -13 20 27 19 17 21 24
Net Nonoperating Obligations (NNO)
-1,106 -1,336 -1,288 -1,191 -1,117 -1,035 -1,428 -1,347 -1,282 -1,192
Total Depreciation and Amortization (D&A)
1.45 2.66 2.19 -9.25 22 -42 -8.35 -8.12 23 2.62
Debt-free, Cash-free Net Working Capital to Revenue
-296.49% -302.24% -349.26% -10.57% -11.02% -14.63% -15.53% -3,330.23% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
702.71% 929.72% 920.61% 336.54% 314.45% 298.35% 301.63% 67,391.48% 0.00% 0.00%
Net Working Capital to Revenue
702.71% 929.72% 920.61% 336.54% 314.45% 298.35% 301.63% 67,391.48% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.84) ($0.75) ($0.80) $1.34 ($0.72) ($0.88) ($0.68) ($0.59) ($0.63) ($0.67)
Adjusted Weighted Average Basic Shares Outstanding
123.47M 125.53M 136.52M 137.05M 137.64M 137.37M 149.40M 168.83M 169.46M 164.47M
Adjusted Diluted Earnings per Share
($0.84) ($0.75) ($0.80) $1.30 ($0.72) ($0.84) ($0.68) ($0.59) ($0.63) ($0.67)
Adjusted Weighted Average Diluted Shares Outstanding
123.47M 125.53M 136.52M 140.93M 137.64M 137.37M 149.40M 168.83M 169.46M 164.47M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
135.81M 136.68M 136.89M 137.42M 138.20M 139.16M 142.61M 143.17M 143.92M 145.22M
Normalized Net Operating Profit after Tax (NOPAT)
-75 -74 -85 119 -80 -93 -93 -82 -86 -91
Normalized NOPAT Margin
-2,114.08% -717.11% -240.66% 40.57% -6,287.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-2,902.47% -921.49% -312.40% 62.35% -7,841.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Denali Therapeutics' Financials

When does Denali Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Denali Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Denali Therapeutics' net income changed over the last 8 years?

Denali Therapeutics' net income appears to be on an upward trend, with a most recent value of -$422.77 million in 2024, rising from -$86.65 million in 2016. The previous period was -$145.22 million in 2023.

What is Denali Therapeutics's operating income?
Denali Therapeutics's total operating income in 2024 was -$487.34 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $487.34 million
How has Denali Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Denali Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2024, a change of 0.0%.

How much debt does Denali Therapeutics have?

Denali Therapeutics' total liabilities were at $144.50 million at the end of 2024, a 17.5% increase from 2023, and a 590.5% increase since 2017.

How much cash does Denali Therapeutics have?

In the past 7 years, Denali Therapeutics' cash and equivalents has ranged from $77.12 million in 2018 to $507.14 million in 2020, and is currently $174.96 million as of their latest financial filing in 2024.

How has Denali Therapeutics' book value per share changed over the last 8 years?

Over the last 8 years, Denali Therapeutics' book value per share changed from 0.00 in 2016 to 8.54 in 2024, a change of 854.4%.



This page (NASDAQ:DNLI) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners